News & Updates
Filter by Specialty:
Show Multimedia Only

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
17 Sep 2025
byStephen Padilla
Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.